• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

促性腺激素释放激素1（GNRH1）和白三烯B4受体（LTB4R）可能是透明细胞肾细胞癌（ccRCC）中与免疫相关的新型预后生物标志物。

GNRH1 and LTB4R might be novel immune-related prognostic biomarkers in clear cell renal cell carcinoma (ccRCC).

作者信息

Wu Hua-Hui, Yan Xin, Chen Zhao, Du Guo-Wei, Bai Xiao-Jie, Tuoheti Kurerban, Liu Tong-Zu

机构信息

Department of Urology, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, 430071, China.

出版信息

Cancer Cell Int. 2021 Jul 6;21(1):354. doi: 10.1186/s12935-021-02052-1.

DOI:10.1186/s12935-021-02052-1
PMID:34229684
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8259034/
Abstract

BACKGROUND

Clear cell renal cell carcinoma (ccRCC) occupied most of renal cell carcinoma (RCC), which associated with poor prognosis. The purpose of this study is to screen novel and prognostic biomarkers for patients with ccRCC.

METHODS AND RESULTS

Firstly, Gene Expression Omnibus database was used to collect microarray data for weighted gene co-expression network construction. Gene modules related to prognosis which interest us most were picked out. 90 hub genes were further chosen in the key modules, two of which including gonadotropin releasing hormone 1 (GNRH1) and leukotriene B4 receptor (LTB4R) were screened and validated as immune-related prognostic biomarkers. Based on several public databases and ccRCC tissues collected by ourselves, we performed survival analysis, spearman correlation analysis, receiver operating characteristic (ROC) analysis, quantitative real-time PCR (qRT-PCR), western blotting, immunofluorescence (IF) and immunohistochemistry (IHC) staining for the validation of immune-related prognostic biomarkers. We further explored the relationship between immune-related prognostic biomarker expressions and immunocytes. Finally, gene set enrichment analysis (GSEA) demonstrated that the two immune-related prognostic biomarkers were significantly correlated with cell cycle.

CONCLUSIONS

Generally speaking, the present study has identified two novel prognostic biomarkers for patients with ccRCC, which showed strong correlation with prognosis of patients with ccRCC, could further be used as potential prognostic biomarkers in ccRCC.

摘要

背景

透明细胞肾细胞癌（ccRCC）占肾细胞癌（RCC）的大部分，其预后较差。本研究的目的是为ccRCC患者筛选新的预后生物标志物。

方法与结果

首先，利用基因表达综合数据库收集微阵列数据用于构建加权基因共表达网络。挑选出我们最感兴趣的与预后相关的基因模块。在关键模块中进一步选择了90个枢纽基因，其中包括促性腺激素释放激素1（GNRH1）和白三烯B4受体（LTB4R）的两个基因被筛选并验证为免疫相关的预后生物标志物。基于几个公共数据库和我们自己收集的ccRCC组织，我们进行了生存分析、斯皮尔曼相关性分析、受试者工作特征（ROC）分析、定量实时PCR（qRT-PCR）、蛋白质免疫印迹、免疫荧光（IF）和免疫组织化学（IHC）染色，以验证免疫相关的预后生物标志物。我们进一步探讨了免疫相关预后生物标志物表达与免疫细胞之间的关系。最后，基因集富集分析（GSEA）表明这两个免疫相关的预后生物标志物与细胞周期显著相关。

结论

总体而言，本研究为ccRCC患者鉴定了两个新的预后生物标志物，它们与ccRCC患者的预后密切相关，可进一步用作ccRCC潜在的预后生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f199/8259034/a36f8a196ccb/12935_2021_2052_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f199/8259034/4d35c49d2f24/12935_2021_2052_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f199/8259034/7b94ba9a6726/12935_2021_2052_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f199/8259034/dad2c7abd5ff/12935_2021_2052_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f199/8259034/cb1ac6a5c208/12935_2021_2052_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f199/8259034/7bdba28a5416/12935_2021_2052_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f199/8259034/51769b03b2df/12935_2021_2052_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f199/8259034/89fa095c7d30/12935_2021_2052_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f199/8259034/978fef25d135/12935_2021_2052_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f199/8259034/a36f8a196ccb/12935_2021_2052_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f199/8259034/4d35c49d2f24/12935_2021_2052_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f199/8259034/7b94ba9a6726/12935_2021_2052_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f199/8259034/dad2c7abd5ff/12935_2021_2052_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f199/8259034/cb1ac6a5c208/12935_2021_2052_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f199/8259034/7bdba28a5416/12935_2021_2052_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f199/8259034/51769b03b2df/12935_2021_2052_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f199/8259034/89fa095c7d30/12935_2021_2052_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f199/8259034/978fef25d135/12935_2021_2052_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f199/8259034/a36f8a196ccb/12935_2021_2052_Fig9_HTML.jpg

相似文献

1
GNRH1 and LTB4R might be novel immune-related prognostic biomarkers in clear cell renal cell carcinoma (ccRCC).促性腺激素释放激素1（GNRH1）和白三烯B4受体（LTB4R）可能是透明细胞肾细胞癌（ccRCC）中与免疫相关的新型预后生物标志物。
Cancer Cell Int. 2021 Jul 6;21(1):354. doi: 10.1186/s12935-021-02052-1.
2
Identification of CXCL13 as a potential biomarker in clear cell renal cell carcinoma via comprehensive bioinformatics analysis.通过综合生物信息学分析鉴定 CXCL13 作为透明细胞肾细胞癌的潜在生物标志物。
Biomed Pharmacother. 2019 Oct;118:109264. doi: 10.1016/j.biopha.2019.109264. Epub 2019 Aug 4.
3
Functional Assessment of Four Novel Immune-Related Biomarkers in the Pathogenesis of Clear Cell Renal Cell Carcinoma.四种新型免疫相关生物标志物在透明细胞肾细胞癌发病机制中的功能评估
Front Cell Dev Biol. 2021 Mar 16;9:621618. doi: 10.3389/fcell.2021.621618. eCollection 2021.
4
Identification of a Novel Immune-Related Prognostic Biomarker and Small-Molecule Drugs in Clear Cell Renal Cell Carcinoma (ccRCC) by a Merged Microarray-Acquired Dataset and TCGA Database.通过合并微阵列获取的数据集和TCGA数据库鉴定透明细胞肾细胞癌（ccRCC）中一种新型免疫相关预后生物标志物和小分子药物
Front Genet. 2020 Aug 18;11:810. doi: 10.3389/fgene.2020.00810. eCollection 2020.
5
STK4 is a prognostic biomarker correlated with immune infiltrates in clear cell renal cell carcinoma.STK4 是与透明细胞肾细胞癌免疫浸润相关的预后生物标志物。
Aging (Albany NY). 2023 Oct 20;15(20):11286-11297. doi: 10.18632/aging.205127.
6
Co-expression network analysis identified FCER1G in association with progression and prognosis in human clear cell renal cell carcinoma.共表达网络分析鉴定出 FCER1G 与人类肾透明细胞癌的进展和预后相关。
Int J Biol Sci. 2017 Nov 1;13(11):1361-1372. doi: 10.7150/ijbs.21657. eCollection 2017.
7
The Landscape of Iron Metabolism-Related and Methylated Genes in the Prognosis Prediction of Clear Cell Renal Cell Carcinoma.铁代谢相关及甲基化基因在透明细胞肾细胞癌预后预测中的图景
Front Oncol. 2020 May 22;10:788. doi: 10.3389/fonc.2020.00788. eCollection 2020.
8
Construction of Competitive Endogenous RNA Network and Verification of 3-Key LncRNA Signature Associated With Distant Metastasis and Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma.透明细胞肾细胞癌患者中竞争性内源性RNA网络的构建及与远处转移和不良预后相关的3个关键长链非编码RNA特征的验证
Front Oncol. 2021 Mar 24;11:640150. doi: 10.3389/fonc.2021.640150. eCollection 2021.
9
Expression of basement membrane genes and their prognostic significance in clear cell renal cell carcinoma patients.基底膜基因在透明细胞肾细胞癌患者中的表达及其预后意义
Front Oncol. 2022 Oct 24;12:1026331. doi: 10.3389/fonc.2022.1026331. eCollection 2022.
10
Fifteen hub genes associated with progression and prognosis of clear cell renal cell carcinoma identified by coexpression analysis.通过共表达分析鉴定出与透明细胞肾细胞癌进展和预后相关的 15 个枢纽基因。
J Cell Physiol. 2019 Jul;234(7):10225-10237. doi: 10.1002/jcp.27692. Epub 2018 Nov 11.

引用本文的文献

1
Consequences of platelet-educated cancer cells on the expression of inflammatory and metastatic glycoproteins.受过血小板影响的癌细胞对炎症和转移糖蛋白表达的影响。
PLoS One. 2025 Mar 17;20(3):e0317096. doi: 10.1371/journal.pone.0317096. eCollection 2025.
2
FAP promotes clear cell renal cell carcinoma progression via activating the PI3K/AKT/mTOR signaling pathway.家族性腺瘤性息肉病通过激活PI3K/AKT/mTOR信号通路促进肾透明细胞癌进展。
Cancer Cell Int. 2023 Sep 27;23(1):217. doi: 10.1186/s12935-023-03073-8.
3
Lipids as Targets for Renal Cell Carcinoma Therapy.

本文引用的文献

1
Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.超越传统免疫检查点抑制——肾细胞癌的新型免疫疗法
Nat Rev Clin Oncol. 2021 Apr;18(4):199-214. doi: 10.1038/s41571-020-00455-z. Epub 2021 Jan 12.
2
Cancer Statistics, 2021.癌症统计数据，2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
3
Combination therapy in metastatic renal cell carcinoma: Back to the future?转移性肾细胞癌的联合治疗：回到未来？
脂质作为肾癌治疗的靶点。
Int J Mol Sci. 2023 Feb 7;24(4):3272. doi: 10.3390/ijms24043272.
4
LTB4R Promotes the Occurrence and Progression of Clear Cell Renal Cell Carcinoma (ccRCC) by Regulating the AKT/mTOR Signaling Pathway.LTB4R 通过调控 AKT/mTOR 信号通路促进肾透明细胞癌（ccRCC）的发生发展。
Cells. 2022 Nov 15;11(22):3606. doi: 10.3390/cells11223606.
5
Bioinformatics analysis of immune-related prognostic genes and immunotherapy in renal clear cell carcinoma.生物信息学分析肾透明细胞癌免疫相关预后基因与免疫治疗。
PLoS One. 2022 Nov 23;17(11):e0272542. doi: 10.1371/journal.pone.0272542. eCollection 2022.
6
Effects and Prognostic Values of Circadian Genes CSNK1E/GNA11/KLF9/THRAP3 in Kidney Renal Clear Cell Carcinoma via a Comprehensive Analysis.通过综合分析探讨昼夜节律基因CSNK1E/GNA11/KLF9/THRAP3在肾透明细胞癌中的作用及预后价值
Bioengineering (Basel). 2022 Jul 11;9(7):306. doi: 10.3390/bioengineering9070306.
7
An Aging and Senescence-Related Gene Signature for Prognosis Prediction in Clear Cell Renal Cell Carcinoma.用于透明细胞肾细胞癌预后预测的衰老和衰老相关基因特征
Front Genet. 2022 May 13;13:871088. doi: 10.3389/fgene.2022.871088. eCollection 2022.
8
m7G Methylation-Related Genes as Biomarkers for Predicting Overall Survival Outcomes for Hepatocellular Carcinoma.m7G甲基化相关基因作为预测肝细胞癌总生存结果的生物标志物
Front Bioeng Biotechnol. 2022 May 10;10:849756. doi: 10.3389/fbioe.2022.849756. eCollection 2022.
Semin Oncol. 2020 Dec;47(6):361-366. doi: 10.1053/j.seminoncol.2020.10.003. Epub 2020 Oct 24.
4
The role of exosomal PD-L1 in tumor progression and immunotherapy.外泌体 PD-L1 在肿瘤进展和免疫治疗中的作用。
Mol Cancer. 2019 Oct 23;18(1):146. doi: 10.1186/s12943-019-1074-3.
5
Trial watch: dendritic cell vaccination for cancer immunotherapy.试验观察：用于癌症免疫治疗的树突状细胞疫苗接种
Oncoimmunology. 2019 Jul 18;8(11):e1638212. doi: 10.1080/2162402X.2019.1638212. eCollection 2019.
6
Prognostic value and immune infiltration of novel signatures in clear cell renal cell carcinoma microenvironment.新型特征在肾透明细胞癌微环境中的预后价值及免疫浸润
Aging (Albany NY). 2019 Sep 7;11(17):6999-7020. doi: 10.18632/aging.102233.
7
Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma.局部透明细胞肾细胞癌中免疫基因表达特征和肿瘤浸润免疫细胞的预后影响。
J Immunother Cancer. 2019 May 28;7(1):139. doi: 10.1186/s40425-019-0621-1.
8
Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.转移性透明细胞肾细胞癌一线治疗的现有和新兴疗法。
Cancer Treat Rev. 2018 Nov;70:127-137. doi: 10.1016/j.ctrv.2018.07.009. Epub 2018 Jul 20.
9
Understanding the tumor immune microenvironment (TIME) for effective therapy.理解肿瘤免疫微环境（TIME）以实现有效的治疗。
Nat Med. 2018 May;24(5):541-550. doi: 10.1038/s41591-018-0014-x. Epub 2018 Apr 23.
10
Intratumoral immunotherapy: using the tumor as the remedy.瘤内免疫治疗：利用肿瘤作为治疗手段。
Ann Oncol. 2017 Dec 1;28(suppl_12):xii33-xii43. doi: 10.1093/annonc/mdx683.